Recent insider trends for Cytori Therapeutics, Inc. (NASDAQ:CYTX) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of CYTX, the data has a lot to say about how the stock might perform going forward.
Institutions own 07.39% of Cytori Therapeutics, Inc. (CYTX)’s shares. The total value of these holdings, in millions, is $1. Among active positions in the latest quarter, 11 holders increased their positions by a total of 272271 shares, 13 holders decreased the positions by a total of 1.78 million shares, and 11 holders held their positions. This works out to a net decrease in ownership of 1.5 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 4 holders initiated new positions by a total of 84085 shares and 4 holders exited their positions by a total of 1.64 million shares. This nets out to a decrease of 1.56 million shares and is another bearish sign for CYTX.
In the last three months, insiders executed a total of 3 trades. 3 were sells. Insider ownership decreased by a total of 188426 shares, which suggests that CYTX’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 3 sells, and ownership decreased by a net of 188426 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Cytori Therapeutics, Inc. (NASDAQ:CYTX)’s short interest is 1.81 million shares, or 8.21% of the float. This represents a decrease of -8% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that CYTX is a Weak buy, which implies that CYTX is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that Cytori Therapeutics, Inc. (NASDAQ:CYTX) is undervalued.